HBV
Beyond's analysis on HBV
- — AusperBio secures $120 million Series C to push AHB‑137 toward Phase 3 and expand its HBV pipeline
- — Brii Biosciences shares interim results highlighting HBV cure progress and vaccine advancement backed by a solid cash position
- — Hepatitis D awareness campaign highlights testing gaps for hepatitis B patients